APX001-202 (#790)
Laufzeit: 01.01.2020 - 31.12.2040
Kurzfassung
A phase 2, open-label study to evaluate the safety and efficacy of APX001 in the treatment of patients with invasive mold infections caused by aspergillus species or rare molds
Laufzeit: 01.01.2020 - 31.12.2040
A phase 2, open-label study to evaluate the safety and efficacy of APX001 in the treatment of patients with invasive mold infections caused by aspergillus species or rare molds
